VolitionRX Ltd
volition.comWhat Do They Do?
Develops and sells blood tests and research tools that help veterinarians, clinicians, and drug developers detect and monitor cancers and other diseases.
10-K for FY2025, filed Mar 31, 2026Volition is a multi-national epigenetics company. It has patented technologies that use chromosomal structures, such as nucleosomes, and…View ↗
Nu.Q® Vet - cost-effective, easy-to-use blood tests for dogs and other companion animals. The Nu.Q® Vet Cancer Test is commercially…View ↗
Our Nu.Q® NETs assay is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis. Our assay can be used to…View ↗
Nu.Q® Discover is a complete solution to profiling nucleosomes which empowers drug developers and scientists, offering rapid epigenetic…View ↗
How Do They Make Money?
Customers pay for Nu.Q Vet tests, nucleosomes and research-use kits when goods ship; third parties pay for lab work when Volition performs it. Licensing deals may bring upfront and later payments, while royalties are based on licensees’ sales.
10-K for FY2025, filed Mar 31, 2026The Company generates product revenues from the sale of its Nu.Q® Vet Cancer Test, from the sale of nucleosomes, and from the sale of…View ↗
The Company receives royalty revenue on the net sales recognized during the period in which the revenue is earned, and the amount is…View ↗
The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is…View ↗
The Company includes revenue recognized from laboratory services performed in the Company’s laboratory on behalf of third parties under…View ↗
For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside…View ↗
Our future as an operating business will depend on our ability to obtain sufficient capital contributions, financing and/or generate…View ↗
$1.7M
-
10-K for FY2025, filed Mar 31, 2026
$1.7M ↗
Who Are Their Customers?
Veterinarians can obtain the Nu.Q Vet test through distributors. Drug developers and scientists work with Volition on nucleosome profiling, and other third parties use its laboratory services.
10-K for FY2025, filed Mar 31, 2026Our test can be easily integrated into preventive care programs and used alongside other routine bloodwork during regular wellness visits.…View ↗
Nu.Q® Discover is a complete solution to profiling nucleosomes which empowers drug developers and scientists, offering rapid epigenetic…View ↗
The Company generates product revenues from the sale of its Nu.Q® Vet Cancer Test, from the sale of nucleosomes, and from the sale of…View ↗
Do Revenues Turn Into Profits?
No. It lost $23.4M in FY2025.
10-K for FY2025, filed Mar 31, 2026
−$21.7MView ↗
10-K for FY2025, filed Mar 31, 2026
−$23.4MView ↗
10-K for FY2025, filed Mar 31, 2026
−$19.8MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$7.3MView ↗
- ▲ +17% (Loss)
- vs −$6.3M in Q2 FY2025
-
Apr 23, 2026
NYSE American accepts plan to regain listing compliance
The exchange granted until August 6, 2027 to regain compliance and may begin delisting proceedings if Volition does not meet the plan.
Sources
8-K, filed Apr 23, 2026
On April 22, 2026, the Company received a notification (the “Acceptance Letter”) from the NYSE American that the Company’s previously…View ↗
Growing. Revenue grew 19.2x in 4 years, from $90K in FY2021 to $1.7M in FY2025, about 109% a year.
Separate DNA-capture approach
The older report framed the product pillars as using the Nu.Q platform and described Nu.Q Capture; the latest report presents Capture-PCR and Capture-Seq separately as methods for isolating tumor-derived DNA fragments.
10-K for FY2022, filed Mar 15, 2023
Who Do They Compete With?
Competes with Exact Sciences, Guardant Health, GRAIL, Natera, Caris Life Sciences, Freenome Holdings, CellMax Life, Archer DX, Foundation Medicine, Oncocyte, OpKo Health, MDNA Life Sciences, Abbott Laboratories, Cepheid, Hologic, Agilent Technologies, Qiagen, Thermo Fisher, Illumina, and One Health
10-K for FY2025, filed Mar 31, 2026We face competition primarily from other human-focused healthcare, pharmaceutical and diagnostic companies such as Exact Sciences…View ↗
Loading...
